



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**JS-6**

UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA  
SOUTHERN DIVISION

MASIMO CORPORATION, et al.,	)	Case No. 8:18-CV-02001-JVS-JDE
Plaintiffs/Counterdefendants,	)	
	)	FINDINGS OF FACT &
v.	)	CONCLUSIONS OF LAW
	)	
TRUE WEARABLES, INC., et al.,	)	Redacted
Defendants/Counterclaimants	)	
	)	
	)	

## TABLE OF CONTENTS

I. Bench Trial Background.....	1
II. Party Background.....	2
III. Findings of Fact and Conclusions of Law.....	4
A. Jurisdiction and Venue.....	4
B. Witness Testimony.....	5
C. Breach of Contract.....	5
Defense: Void Contracts.....	9
D. Breach of Fiduciary Duty.....	9
Defense: Statute of Limitations.....	15
E. Trade Secrets.....	18
Trade Secret 1.....	19
Trade Secret 5.....	23
Trade Secret 8.....	25
Trade Secret 9.....	28
Trade Secret 11.....	32
Trade Secret 12.....	35
Willfulness & Maliciousness.....	39
Defenses.....	40
F. The '848 Patent.....	42
Infringement.....	42
Invalidity.....	51
Level of Ordinary Skill in the Art.....	53
Scope and Content of Prior Art.....	53
Motivation to Combine.....	55
Reasonable Expectation of Success.....	57
Other Indicia of Nonobviousness.....	58
G. Other Affirmative Defenses.....	59
H. Equitable Remedies.....	59
Breach of Fiduciary Duty.....	59
Trade Secrets - Injunctive Relief.....	60
Breach of Contract - Injunctive Relief.....	62
Patent Applications Containing Trade Secrets.....	62
Restraint on Employment.....	65
Attorney's Fees.....	66
IV. Summary of Conclusions of Law.....	67
V. Conclusion.....	72

1 After Plaintiffs waived their right to a jury trial (Dkt. 398), the Court  
2 presided over a bench trial. See Dkts.552, 553, 555, 556, 557. The Court received  
3 direct testimony via declaration before holding in-person proceedings for cross-  
4 examination, redirect, and recross. At the conclusion of trial, the parties submitted  
5 closing briefs (Dkts. 576-1, 579-1) and the Court held closing argument. See Dkt.  
6 583. Under Rule 52(a) of Federal Rules of Civil Procedure, the Court now enters  
7 its findings of fact and conclusions of law.

8  
9 **I. Bench Trial Background**

10  
11 Plaintiffs' First Amended Complaint (Dkt. 42), Defendants' Answer and  
12 Counterclaims (Dkt. 46), and Plaintiffs' Answer to Counterclaims (Dkt. 49) are the  
13 operative pleadings. In sum, before trial the case was narrowed to encompass only  
14 the following claims and related defenses:

- 15 • Breach of contract: Whether Defendant, Dr. Marcelo Lamego, breached  
16 contracts with Plaintiffs, Masimo Corporation and Cercacor Labs, based on  
17 his employee confidentiality agreements, and whether those agreements are  
18 void as a restraint on trade;
- 19 • Breach of fiduciary duty: Whether Dr. Lamego breached his fiduciary duty  
20 of undivided loyalty to Cercacor based on representations made to the board  
21 of directors, and whether this claim is barred by the statute of limitations;
- 22 • Trade secret misappropriation: Whether Defendants misappropriated any of  
23 Trade Secrets 1, 5, 8, 9, 11, and/or 12 under Cal. Civ. Code § 3246.1  
24 (CUTSA), and whether related defenses apply;
- 25 • Patent infringement: Whether Defendants infringe Claim 9 of the U.S. Patent  
26 No. 10,194,848, and whether Claim 9 is invalid for obviousness; and  
27 • What, if any, equitable relief should be afforded to the parties?

28 See Dkt. 508 (Amended Joint Final Pretrial Conference Order).

1 **II. Party Background**

2  
3 Plaintiff Masimo Corporation is a leader in pulse oximetry, which involves  
4 measuring oxygen in the blood. Joe Kiani founded Masimo in 1989. Kiani believed  
5 he could solve the “motion problem” in pulse oximetry, which prevented accurate  
6 pulse oximetry measurements when the patient was moving, leading to false  
7 alarms. Mohamed Diab is a scientist who joined Masimo about six months after its  
8 founding. Diab designed circuits and wrote the software that Masimo used to  
9 develop pulse oximetry technology. A pulse oximeter works by attaching a sensor  
10 to a patient to detect a physiological signal. Light sources in the sensor transmit  
11 light through the patient’s tissue. The amount of light absorbed by the tissue and  
12 the corresponding detected signal can provide information about the patient’s  
13 blood flow and blood content such as oxygen saturation (“SpO<sub>2</sub>”). The detected  
14 signal is called a photoplethysmogram, photoplethysmograph, pleth, or “PPG” for  
15 short.

16 Historically, motion at the measurement site could corrupt the PPG and  
17 result in “noisy” and unreliable data. By the early 1990s, Kiani and Diab had  
18 discovered their first solution to the motion problem in pulse oximetry and had  
19 developed multiple algorithms for measuring oxygen saturation. Masimo named its  
20 technology Masimo “SET” for Signal Extraction Technology. Masimo also began  
21 working on an improved pulse rate algorithm. Masimo patented some of its  
22 technology and kept other aspects secret.

23 In 1998, Masimo Corp. spun off Cercacor (formerly known as Masimo  
24 Laboratories) to carry forward some portions of Masimo’s business that were still  
25 in research and development. Kiani became Cercacor CEO, and Diab became the  
26 first employee, where he continued to work closely with Masimo. Masimo and  
27 Cercacor have a cross-licensing agreement that allows them to work together  
28 confidentially on new technologies. For example, Cercacor has focused on glucose

1 and other non-invasive parameters. Masimo and Cercacor refer to these parameters  
2 as “rainbow” parameters and named the technology “rainbow SET.” Under the  
3 relevant cross-licensing agreement, Masimo uses Cercacor’s technology and pays  
4 Cercacor a license fee and royalties.

5 Defendant Dr. Marcelo Lamego holds a Ph.D. in Electrical and Electronics  
6 Engineering from Stanford University. Upon graduating from Stanford in 2000,  
7 Dr. Lamego obtained employment as an Algorithm Engineer at Masimo  
8 Corporation. Dr. Lamego signed his first confidentiality agreement at that time.  
9 See JTX-307. In 2000, Dr. Lamego worked at Masimo for approximately six  
10 months. From 2001 to 2003, he joined the Boston Consulting Group, in São Paulo,  
11 Brazil, where he also worked as a professor at the University of São Paulo,  
12 teaching in the MBA program for Management and Product Engineering.

13 In January 2003, Masimo re-hired Dr. Lamego as a Research Scientist. At  
14 that time, Dr. Lamego signed a second Masimo confidentiality agreement. See  
15 JTX-308. In 2005, Dr. Lamego signed a third Masimo confidentiality agreement.  
16 See JTX-309.

17 In February 2007, after Diab began having health problems, Kiani selected  
18 Dr. Lamego as Masimo Labs’ (now Cercacor) next Chief Technology Officer  
19 (CTO). To facilitate this transition, Masimo exposed Dr. Lamego to its technology,  
20 including providing access to Masimo’s confidential information, such as the  
21 rainbow SET source code. Dr. Lamego also shared an office with Diab. Dr.  
22 Lamego was one of twelve employees with access to all rainbow directories on  
23 Masimo’s network. See JTX-20; JTX-26. In his new role as CTO, Dr. Lamego  
24 signed another confidentiality agreement, agreeing that his work product would  
25 belong to Cercacor and that he would not use or disclose confidential information  
26 if he left Cercacor. See JTX-310.

27 From February 2007 to January 2014, Dr. Lamego served as Cercacor’s  
28 CTO. In this role, he was responsible for the engineering team and Cercacor’s

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.